Trial site
ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z o. o.
Tarnów, 33-100, PolandEU-13 widening countryNot linked to an institution yet
- 12running trials
- 9closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 29 trials
- Phase 2/31 trial
- Phase 41 trial
- Status
- Completed9 trials
- Active, not recruiting7 trials
- Recruiting3 trials
- Not yet recruiting2 trials
- Lead sponsor
- Pfizer3 trials
- Sanofi3 trials
- Chiesi Farmaceutici S.p.A.2 trials
- Almirall, S.A.1 trial
- Amgen1 trial
- and 11 more
Running trials
Recruiting
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
NCT07666490· Phase 4· Chiesi Farmaceutici S.p.A.· Source
Active, not recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· Phase 2· UCB Biopharma SRL· Source
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615· Phase 2· Pfizer· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581· Phase 2· Pfizer· Source
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682· Phase 3· LEO Pharma· Source
Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated with Dupilumab.
NCT05694884· Phase 2· Aslan Pharmaceuticals Pte Ltd· Source
Active, not recruiting
A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma
2022-502984-39-00· Phase 3· AstraZeneca AB· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471· Phase 3· Incyte Corporation· Source
Terminated
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156· Phase 2· Sanofi· Source
Recruiting
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
NCT05222529· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· Phase 2/3· Sanofi· Source
Active, not recruiting
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
NCT04708041· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error